1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

F-star asset-centric spin-out to target HER2

 
• By Gemma Collier

Making the transition from platform- to product-based operation is a quantum operation, at least for Cambridge antibody company, F-star. The company has won €9.4m from its existing investor pool but the money will go into a separate and unencumbered asset-development vehicle, F-star Alpha which will operate virtually in developing a few of the company's bi-specific antibody candidates. And the lead program will take F-star Alpha into the increasing crowded area of Her2-targeted cancer therapies.

Making the transition from platform- to product-based operation is a quantum operation, at least for Cambridge antibody company, F-star. The company has won €9.4m from its existing investor pool but the money will go into a separate and unencumbered asset-development vehicle, F-star Alpha which will operate virtually in developing a few of the company's bi-specific antibody candidates. And the lead program will take F-star Alpha into the increasing crowded area of Her2-targeted cancer therapies.

The asset-centric approach is designed to create opportunities with this fundraising process. It involves placing each of F-star's assets in its own vehicle company to allow the firm more flexibility...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

More from Therapy Areas

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.